




RealRate

PHARMACEUTICAL 2021

Y mAbs Therapeutics Inc
Rank 209 of 394



The relative strengths and weaknesses of Y mAbs Therapeutics Inc are analyzed with respect to the market average, including all of its competitors. We analyzed all variables having an effect on the Economic Capital Ratio.

The greatest strength of Y mAbs Therapeutics Inc compared to the market average is the variable Liabilities, increasing the Economic Capital Ratio by 75% points. The greatest weakness of Y mAbs Therapeutics Inc is the variable Expenses, reducing the Economic Capital Ratio by 49% points.

The company's Economic Capital Ratio, given in the ranking table, is 261%, being 4.5% points above the market average of 256%.

Input Variable	Value in 1000 USD
Assets, Current	122,363
Cost of Goods Sold	0
Intangible Assets	0
Liabilities, Current	19,535
Liabilities, Non-Current	3,981
Other Assets	7,859
Other Compr. Net Income	-576
Other Expenses	2,203
Other Liabilities	2,695
Other Net Income	598
Other Revenues	20,750
Property and Equipment	1,825
Research and Development	93,697
Selling, General and Administrative Expense	44,785

Output Variable	Value in 1000 USD
Assets	132,047
Liabilities	26,211
Expenses	140,685
Revenues	20,750
Stockholders Equity	105,836
Net Income	-119,337
Comprehensive Net Income	-119,625
BaseVar	160,434
ECR before LimitedLiability	140%
Economic Capital Ratio	261%